Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan
Details : Ustekinumab, a biosimilar of Stelara, is a monoclonal antibody used to treat several autoimmune conditions and Denosumab, a biosimilar referencing Prolia®, is a monoclonal antibody for the treatment of osteoporosis.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 17, 2022
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?